# Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

> **NCT06839456** · PHASE1,PHASE2 · RECRUITING · sponsor: **Children's Hospital of Philadelphia** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia
- High Risk Acute Lymphoblastic Leukemia
- High Risk Acute Myeloid Leukemia
- Relapse Leukemia
- MDS (Myelodysplastic Syndrome)
- Relapsed Non-Hodgkin Lymphoma
- Acquired Aplastic Anemia
- Inherited BMF Syndrome
- Immunodeficiency
- Primary Immune Regulatory Disorder
- Hemoglobinopathies
- Bone Marrow Failure
- Inborn Errors of Metabolism
- HLH

## Interventions

- **DEVICE:** Phase 1 Dose Level 1
- **DEVICE:** Phase 1 Dose Level 2
- **DEVICE:** Phase 1 Dose Level 3
- **DEVICE:** Phase 2 Maximum Tolerated Dose determined in Phase 1
- **DEVICE:** Phase 2 Established Dose from prior study, NCT03810196

## Key facts

- **NCT ID:** NCT06839456
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2031-03
- **Final completion:** 2032-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06839456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06839456, "Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06839456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*